La Jolla Pharmaceutical Company – Amendment to Executive Employment Agreement (March 31st, 2009)
This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (Amendment), dated as of December 29, 2008, is between La Jolla Pharmaceutical Company, a Delaware corporation, with its principal place of business located at 6455 Nancy Ridge Drive, San Diego, California 92121 (the Employer), and Jessie Elchico (the Employee).
La Jolla Pharmaceutical Company – Contract (October 7th, 2005)
EXHIBIT 10.5 October 6, 2005 Josefina T. Elchico La Jolla Pharmaceutical Company 6455 Nancy Ridge Drive San Diego, California 92121 Dear Jessie, In order to continue to retain your services and to incentivize you to continue as an employee, subject to the terms of this letter agreement (this "Agreement"), La Jolla Pharmaceutical Company (the "Company") hereby offers to pay to you a success bonus, the payment of which is conditioned upon the Company's achievement of the strategic objectives identified herein. 1. Strategic Objectives. As part of this Agreement, you agree to continue to make a valuable contribution to the Company and to assist the Company with the assessment and implementation of the strategic alternatives the Company may choose to pursue and to continue to contribute to the development of Riquent(R) and the Company's other drug development efforts. You also agree to continue to work towards c
La Jolla Pharmaceutical Company – Contract (August 9th, 2005)
EXHIBIT 10.63 August 9, 2005 Josefina T. Elchico La Jolla Pharmaceutical Company 6455 Nancy Ridge Drive San Diego, California 92121 Dear Jessie, On April 19, 2005, you and La Jolla Pharmaceutical Company (the "Company") entered into an agreement (the "Retention Agreement") which provided you with the potential to earn bonuses upon the occurrence of certain events. The purpose of this letter is to clarify how the Retention Agreement would operate in the context of certain transactions not expressly addressed in the Retention Agreement in order to continue to retain your services and to incentivize you to remain an employee of the Company. 1. If, on or prior to September 30, 2005, the Company executes a definitive agreement that provides for a sale of equity securities that results in the Company receiving gross proceeds (before expenses) of $50 million or more, the Company will pay you the Riquent Bonus (as such term is defined in the Retention Agreement). In this c
La Jolla Pharmaceutical Company – Contract (November 5th, 2004)
EXHIBIT 10.31 ATTACHMENT B As a supplement to the letter agreement dated October 7, 2004 between La Jolla Pharmaceutical Company ("LJP") and Josefina Elchico. ("ELCHICO") related to Elchico's employment by LJP, Elchico and LJP hereby agree as follows: In connection with Elchico's employment with LJP, LJP's management will recommend to LJP's Board of Directors that LJP grant to Elchico an option to purchase up to 50,000 shares of common stock of LJP. Such option, if granted, shall be the "OPTION" for purposes hereof. If Elchico's employment is terminated by LJP without cause (as defined below), or if a Change in Control of LJP (as defined below) occurs and Elchico's employment with LJP or its successor "terminates in connection with" (as defined below) that Change in Control and in the absence of any event or circumstance constituting Cause, then: (i) Elchico will be entitled to receive from LJP a severance payment